Log in

NASDAQ:SVRASavara Stock Price, Forecast & News

$2.52
+0.10 (+4.13 %)
(As of 05/27/2020 04:00 PM ET)
Add
Compare
Today's Range
$2.32
Now: $2.52
$2.54
50-Day Range
$2.03
MA: $2.34
$2.56
52-Week Range
$0.69
Now: $2.52
$11.42
Volume288,011 shs
Average Volume444,084 shs
Market Capitalization$131.51 million
P/E RatioN/A
Dividend YieldN/A
Beta0.94
Savara Inc., formerly Mast Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients. Molgradex is an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor. It is developing Molgradex for the treatment of autoimmune pulmonary alveolar proteinosis, a rare lung disease. AIR001 is a sodium nitrite solution for inhalation via nebulization. AIR001 is in Phase II clinical development for the treatment of heart failure with preserved ejection fraction, also known as diastolic heart failure or heart failure with preserved systolic function.
Read More
Savara logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.3Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.47 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:SVRA
CUSIPN/A
Phone512-614-1848

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Cash Flow$5.25 per share
Book Value$1.67 per share

Profitability

Net Income$-78,170,000.00

Miscellaneous

EmployeesN/A
Market Cap$131.51 million
Next Earnings Date8/13/2020 (Estimated)
OptionableOptionable

Receive SVRA News and Ratings via Email

Sign-up to receive the latest news and ratings for SVRA and its competitors with MarketBeat's FREE daily newsletter.

Savara (NASDAQ:SVRA) Frequently Asked Questions

How has Savara's stock been impacted by COVID-19 (Coronavirus)?

Savara's stock was trading at $2.36 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, SVRA shares have increased by 6.8% and is now trading at $2.52. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Savara?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Savara in the last year. There are currently 2 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Savara.

When is Savara's next earnings date?

Savara is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Savara.

How were Savara's earnings last quarter?

Savara Inc (NASDAQ:SVRA) posted its earnings results on Thursday, May, 7th. The company reported ($0.27) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.28) by $0.01. View Savara's earnings history.

What price target have analysts set for SVRA?

5 brokerages have issued 12 month price targets for Savara's shares. Their forecasts range from $1.00 to $17.00. On average, they anticipate Savara's share price to reach $8.32 in the next year. This suggests a possible upside of 230.2% from the stock's current price. View analysts' price targets for Savara.

Has Savara been receiving favorable news coverage?

Media stories about SVRA stock have trended positive this week, according to InfoTrie Sentiment. The research group identifies negative and positive media coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Savara earned a news impact score of 2.5 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View the latest news aboutSavara.

Who are some of Savara's key competitors?

What other stocks do shareholders of Savara own?

Who are Savara's key executives?

Savara's management team includes the following people:
  • Robert N. Neville, Chairman of the Board, Chief Executive Officer (Age 51)
  • Taneli Jouhikainen, President, Chief Operating Officer (Age 51)
  • David L. Lowrance, Chief Financial Officer (Age 50)
  • Nevan C. Elam, Independent Director (Age 49)
  • Richard J. Hawkins, Independent Director (Age 68)
  • Joseph S. McCracken Ph.D., Independent Director (Age 64)
  • Matthew Pauls J.D., Independent Director (Age 46)
  • Yuri Pikover, Independent Director (Age 56)

What is Savara's stock symbol?

Savara trades on the NASDAQ under the ticker symbol "SVRA."

Who are Savara's major shareholders?

Savara's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (4.52%), AXA (2.57%), State Street Corp (1.06%), Geode Capital Management LLC (0.92%), Acadian Asset Management LLC (0.43%) and Dupont Capital Management Corp (0.22%). Company insiders that own Savara stock include David A Ramsay, David L Lowrance, Jaakko Taneli Jouhikainen, Richard J Hawkins and Robert N Neville. View institutional ownership trends for Savara.

Which institutional investors are selling Savara stock?

SVRA stock was sold by a variety of institutional investors in the last quarter, including Two Sigma Advisers LP, Deutsche Bank AG, and UBS Group AG. View insider buying and selling activity for Savara.

Which institutional investors are buying Savara stock?

SVRA stock was acquired by a variety of institutional investors in the last quarter, including AXA, Acadian Asset Management LLC, Dupont Capital Management Corp, Geode Capital Management LLC, Intellectus Partners LLC, BlackRock Inc., SG Americas Securities LLC, and Bank of New York Mellon Corp. Company insiders that have bought Savara stock in the last two years include David A Ramsay, and Robert N Neville. View insider buying and selling activity for Savara.

How do I buy shares of Savara?

Shares of SVRA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Savara's stock price today?

One share of SVRA stock can currently be purchased for approximately $2.52.

How big of a company is Savara?

Savara has a market capitalization of $131.51 million. The company earns $-78,170,000.00 in net income (profit) each year or $4.57 on an earnings per share basis.

What is Savara's official website?

The official website for Savara is www.savarapharma.com.

How can I contact Savara?

Savara's mailing address is 900 S. CAPITAL OF TEXAS HIGHWAY SUITE 150, AUSTIN TX, 78746. The company can be reached via phone at 512-614-1848 or via email at [email protected]

This page was last updated on 5/28/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.